Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation

被引:36
作者
Dong, M. [1 ,3 ]
Parsaik, A. K. [1 ]
Eberhardt, N. L. [1 ]
Basu, A. [1 ]
Cosio, F. G. [2 ]
Kudva, Y. C. [1 ]
机构
[1] Mayo Clin, Div Endocrinol Diabet Metab & Nutr, Rochester, MN USA
[2] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN USA
[3] Shandong Univ, Qilu Hosp, Dept Endocrinol & Metab, Jinan 250100, Shandong, Peoples R China
关键词
diabetes mellitus; mechanism; new onset; organ transplantation; RENAL-ALLOGRAFT RECIPIENTS; ISOLATED RAT ISLETS; BETA-CELL; INSULIN-SECRETION; CYCLOSPORINE-A; KIDNEY-TRANSPLANTATION; RISK-FACTORS; CARDIOVASCULAR RISK; STEROID WITHDRAWAL; PANCREATIC-ISLETS;
D O I
10.1111/j.1464-5491.2012.03617.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabet. Med. 29, e1e12 (2012) Abstract New-onset diabetes after transplantation is recognized as one of the metabolic consequences which may increase the risk of morbidity and mortality after solid organ transplantation. The pathophysiology of new-onset diabetes after transplantation has not been clearly defined and may resemble that of Type 2 diabetes, characterized by predominantly insulin resistance or defective insulin secretion, or both. This review aims to summarize the current state of knowledge regarding the prevalence, consequences, pathogenesis, and management of new-onset diabetes after transplantation, with a major focus on the possible mechanisms involved in the pathogenesis of the disorder. The aetiology of new-onset diabetes after transplantation is multifactorial, with diabetogenic immunosuppressive drugs playing a major role. Multiple cellular and physiologic mechanisms are involved in the process. Selection of an appropriate maintenance immunosuppressive regimen should involve balancing the risk of patient and graft survival vs. the potential for new-onset diabetes after transplantation.
引用
收藏
页码:E1 / E12
页数:12
相关论文
共 58 条
  • [1] Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs
    Araki, M
    Flechner, SM
    Ismail, HR
    Flechner, LM
    Zhou, LM
    Derweesh, IH
    Goldfarb, D
    Modlin, C
    Novick, AC
    Faiman, C
    [J]. TRANSPLANTATION, 2006, 81 (03) : 335 - 341
  • [2] mTORC1 Activation Regulates β-Cell Mass and Proliferation by Modulation of Cyclin D2 Synthesis and Stability
    Balcazar, Norman
    Sathyamurthy, Aruna
    Elghazi, Lynda
    Gould, Aaron
    Weiss, Aaron
    Shiojima, Ichiro
    Walsh, Kenneth
    Bernal-Mizrachi, Ernesto
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (12) : 7832 - 7842
  • [3] New-onset diabetes after transplantation: a review of recent literature
    Balla, Ashfaq
    Chobanian, Michael
    [J]. CURRENT OPINION IN ORGAN TRANSPLANTATION, 2009, 14 (04) : 375 - 379
  • [4] IL-6 promoter polymorphism-174 is associated with new-onset diabetes after transplantation
    Bamoulid, Jamal
    Courivaud, Cecile
    Deschamps, Marina
    Mercier, Patricia
    Ferrand, Christophe
    Penfornis, Alfred
    Tiberghien, Pierre
    Chalopin, Jean-Marc
    Saas, Philippe
    Ducloux, Didier
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (08): : 2333 - 2340
  • [5] Clinical Relevance and Prevalence of Polymorphisms in CYP3A5 and MDR1 Genes That Encode Tacrolimus Biotransformation Enzymes in Liver Transplant Recipients
    Barrera-Pulido, L.
    Aguilera-Garcia, I.
    Docobo-Perez, F.
    Alamo-Martinez, J. M.
    Pareja-Ciuro, F.
    Nunez-Roldan, A.
    Gomez-Bravo, M. A.
    Bernardos-Rodriguez, A.
    [J]. TRANSPLANTATION PROCEEDINGS, 2008, 40 (09) : 2949 - 2951
  • [6] Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients
    Beckebaum, S.
    Klein, C.
    Varghese, J.
    Sotiropoulos, G. C.
    Saner, F.
    Schmitz, K.
    Gerken, G.
    Paul, A.
    Cicinnati, V. R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (08) : 834 - 842
  • [7] Boots JMM, 2002, J AM SOC NEPHROL, V13, P221, DOI 10.1681/ASN.V131221
  • [8] Pilot Study: Association of Traditional and Genetic Risk Factors and New-Onset Diabetes Mellitus Following Kidney Transplantation
    Chakkera, H. A.
    Hanson, R. L.
    Raza, S. M.
    DiStefano, J. K.
    Millis, M. P.
    Heilman, R. L.
    Mulligan, D. C.
    Reddy, K. S.
    Mazur, M. J.
    Hamawi, K.
    Moss, A. A.
    Mekeel, K. L.
    Cerhan, J. R.
    [J]. TRANSPLANTATION PROCEEDINGS, 2009, 41 (10) : 4172 - 4177
  • [9] Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus
    Chang, Horng-Rong
    Yang, Shun-Fa
    Tsai, Jen-Pi
    Hsieh, Ming-Chia
    Wu, Sheng-Wen
    Tsai, Hui-Ching
    Hung, Tung-Wei
    Huang, Jun-Huang
    Lian, Jong-Da
    [J]. CLINICA CHIMICA ACTA, 2011, 412 (3-4) : 322 - 326
  • [10] New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation
    Cosio, FG
    Kudva, Y
    van der Velde, M
    Larson, TS
    Textor, SC
    Griffin, MD
    Stegall, MD
    [J]. KIDNEY INTERNATIONAL, 2005, 67 (06) : 2415 - 2421